Protagonist director Waddill sells 20K PTGX shares

Protagonist Therapeutics director William D. Waddill reported an option exercise and share sale on February 6, 2026.

Rhea-AI Filing Summary

Protagonist Therapeutics director William D. Waddill reported an option exercise and share sale on February 6, 2026. He exercised 20,000 stock options at an exercise price of $8.31 per share and acquired 20,000 common shares.

On the same date, he sold 20,000 common shares at a weighted average price of $83.68 per share, in multiple trades between $83.65 and $83.87. After these transactions, he directly owned 7,825 shares of common stock, and the reported stock options were fully exercised with 0 options remaining.

Insider Trade Summary

Exercise and Sale: 20,000 shares ($1.51M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Waddill William D.

Role Director

Sold 20,000 shs ($1.67M)

Approx. gross sale proceeds $1.67M

Approx. exercise cost $166K

Approx. pre-tax spread $1.51M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	20,000	$0.00	$0.00
Exercise	Common Stock	20,000	$8.31	$166K
Sale	Common Stock	20,000	$83.68	$1.67M

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 7,825 shares (Direct)

Footnotes (2)

1. F1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $83.65 to $83.87. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
2. F2. These stock options are fully vested.

FAQ

What insider transaction did PTGX director William D. Waddill report?

William D. Waddill reported exercising 20,000 stock options and selling 20,000 Protagonist Therapeutics common shares on February 6, 2026. The filing shows both the option exercise price and the weighted average sale price, along with his remaining directly owned share balance afterward.

At what prices did William D. Waddill trade Protagonist Therapeutics (PTGX) shares?

He exercised stock options at an exercise price of $8.31 per share and sold 20,000 common shares at a weighted average price of $83.68. The sales occurred in multiple trades within a price range from $83.65 to $83.87 per share.

How many Protagonist Therapeutics (PTGX) shares does Waddill own after this Form 4?

After the reported transactions, William D. Waddill directly owns 7,825 shares of Protagonist Therapeutics common stock. The Form 4 indicates this balance following the option exercise and subsequent sale of 20,000 shares on February 6, 2026.

What happened to William D. Waddill’s Protagonist Therapeutics stock options?

He exercised 20,000 stock options with a $8.31 exercise price on February 6, 2026. The filing states these stock options are fully vested and shows zero derivative securities beneficially owned following the reported transaction, indicating the options were fully exercised.

What does the weighted average sale price mean in Waddill’s PTGX Form 4?

The weighted average sale price of $83.68 per share reflects multiple sale transactions between $83.65 and $83.87. The filing notes that detailed trade-level pricing information will be provided upon request to the SEC staff, the issuer, or any security holder.

Is William D. Waddill a director or officer of Protagonist Therapeutics (PTGX)?

William D. Waddill is identified as a director of Protagonist Therapeutics in the Form 4. The filing does not list him as an officer or 10% owner, and it specifies that the report is filed by one reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 04:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Waddill William D.

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CA 94560-1160

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		M		20,000	A	$8.31	27,825	D
Common Stock	02/06/2026		S		20,000	D	$83.68(1)	7,825	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.31	02/06/2026		M			20,000	(2)	05/25/2032	Common Stock	20,000	$0.00	0	D

Explanation of Responses:

1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $83.65 to $83.87. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

2. These stock options are fully vested.

	/s/ Matthew Gosling, Attorney-in-Fact for William D. Waddill	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.